Much of the initial interest in AMPK in prostate cancer came from retrospective clinical studies of the antidiabetic drug metformin -a drug that can indirectly activate AMPK [59] [60] [61] [62] -which suggested that metformin decreased the risk of cancer. Accordingly, several reports using pharmacological modulators of AMPK as well as genetic knockout of one of AMPK's catalytic subunits, PRKAA2, support a tumour-suppressive role in prostate cancer 7, 17, [63] [64] [65] . However, subsequent retrospective studies did not find any link between metformin use and decreased cancer risk [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] and, in fact, some studies even suggested that increased metformin use correlated with more aggressive prostate cancer 66, 71 . Importantly, the first prospective clinical trials directly testing the effect of metformin on prostate cancer have recently been completed and showed limited efficacy 78, 79 . Additional preclinical studies using pharmacological, molecular, and genetic approaches have now identified an oncogenic role for AMPK in prostate cancer [29] [30] [31] [33] [34] [35] 37 . Furthermore, levels of threonine-172 phosphory lated (activated) AMPK and serine-80 phosphorylated acetylCoA carboxylase (ACC), a canonical target of AMPK, have been shown to be elevated in prostate cancer clinical samples compared with benign controls 7, 33, 37 . Phosphorylated AMPK levels were also shown to correlate with progression to advanced or recurrent stages of the disease 33 and Gleason score to be context dependent. This confusion has undoubtedly frustrated clinicians and researchers and, therefore, precluded subsequent drug development efforts.
Here, we propose a mechanistic explanation to assist in understanding how AMPK works in prostate cancer and, therefore, to determine when AMPK is functioning in an oncogenic or tumour-suppressive capacity. Specifically, we hypothesize that different subcellular populations of AMPK exist that enable compartmentalized signalling (FIG. 1) . The location of these AMPK complexes is influenced by factors such as subunit composition. Each of these subcellular populations of AMPK will be associated with unique downstream cellular processes (FIG. 2) . Which AMPK populations are activated is determined by the spatial and temporal regulation of diverse upstream stimuli, and the weighted net function of these downstream signalling events, influenced by additional prostate-specific signalling, determines AMPK's final biological output. Our goal is to use our understanding of the factors that regulate AMPK activity, AMPK's known functions, and emerging approaches for targeting AMPK signalling, in order to leverage the proposed model to determine if, how, and when, AMPK could be therapeutically targeted.
Influence of structure and location
The AMPK complex is a heterotrimer consisting of a catalytic α subunit and regulatory β and γ subunits 80, 81 . The N-terminus of the α subunit contains the serine/threonine kinase domain as well as an activation loop that requires phosphorylation at a specific threonine residue -commonly referred to as Thr172 owing to its position in the rat sequence from which it was originally identified 82 -by upstream kinases for full AMPK activation (activity increases >100-fold) 83 . The α subunit C-terminus is required for association with the β subunit, and the α subunit also contains a central autoinhibitory domain. The β subunit contains a central domain that enables it to interact with glycogen and a C-terminal domain that is needed for the association with the α and γ subunits. The γ subunit contains four tandem cystathionine β-synthase (CBS) motifs, three of which can bind nucleotides (site two cannot). Site four seems to constitutively bind AMP, whereas sites one and three bind AMP, ADP, or ATP in a competitive manner 84 . Binding of AMP and/or ADP promotes the phosphorylation of Thr172 on the α subunit by upstream kinases while also inhibiting the dephosphorylation of this same site by phosphatases [85] [86] [87] . These activating actions of AMP and/or ADP are antagonized by ATP. AMP, but not ADP, also causes an allosteric activation (reported to be 2-5-fold but the exact fold induction is still debated 88 ) of the phosphorylated kinase 87 . In fact, this allosteric activation seems to be antagonized by ATP and ADP.
Two genes (PRKAA1 and PRKAA2, respectively) encode the AMPK α1 and α2 catalytic subunits, two (PRKAB1 and PRKAB2, respectively) encode the β1 and β2 regulatory subunits, and three genes (PRKAG1, PRKAG2 and PRKAG3, respectively) encode the γ1, γ2 and γ3 regulatory units 2 . The subunits are expressed to varying degrees in a cell-specific, tissue-specific, and disease-specific manner 2 . In addition, splice variants of the subunits exist 89 . Thus, a minimum of 12 different AMPK complexes can be formed between the seven different subunits.
The compartmentalization of AMPK signalling is an important aspect of AMPK that is often overlooked. Different isoforms of the various subunits can vary in their subcellular localization [90] [91] [92] [93] . For example, the α1 subunit has a predominantly cytoplasmic localization, whereas the α2 subunit can readily shuttle to the nucleus. Additional AMPK subunits have also been found to partly reside in the nucleus 94, 95 . Furthermore, the subcellular localization of subunits can be altered in response to different stimuli 92, 96 . That said, evidence suggests that -under certain conditions such as during circadian rhythms -α1 can also shuttle to the nucleus 97 . Whether this shuttling happens in the prostate and how this process would occur are currently unknown. Importantly, studies in yeast have demonstrated that the subcellular location of the β subunit directs the localization of the catalytic α subunit 93 . This effect has key functional consequences, as it dictates with which subset of downstream targets AMPK can interact and, therefore, phosphorylate.
Relatively little is known regarding AMPK's role, if any, during prostatic development. As double knockout of AMPKα1 and AMPKα2 in mice is lethal at day 10.5 postconception, study of prostate development is difficult in this context. To our knowledge, no prostatespecific conditional AMPKα1/AMPKα2 doubleknockout mouse has been developed. Both AMPKα1 global knockout and AMPKα2 single-knockout mice have been created as well as knockouts of other AMPK subunits 2 . No prostate defects have been reported in any of these animals, but this might simply reflect that the prostate was not examined. AMPKα1 global-knockout mice are subfertile owing to poor sperm quality 98 . A subsequent study using AMPKα1 conditional-knockout mice identified defects in the Sertoli cells as the likely cause 99 . Whether defects in the prostate of the AMPKα1 global knockout mice exist and if these could then also contribute to the decreased fertility is not known. Global knockout of Camkk2, the predominant AMPK upstream kinase in the prostate, in mice did not lead to any overt morphological abnormalities in the prostate , but, interestingly, mouse embryonic fibroblast (MEF) cells generated from these double-knockout mice are resistant to oncogenic transformation 22 . In addition, spontan eous tumour formation has never been observed in α1-deficient or α2-deficient mice, indicating that loss of AMPK itself is not sufficient to cause tumorigenesis 100 . However, deletion of α2 alone increased the growth of RAStransformed MEFs 8 and, by contrast, deletion of α1 alone decreased growth in the same cells 8 . Whereas genetic deletion of the minor isoform, α2, slightly increased the incidence of prostatic intraepithelial neoplasia (PIN) in a fatty acid synthase (FAS)-transgenic model of mouse prostate hyperplasia 17 , knockdown of either the predominant α1 alone or double knockdown of α1 and α2 decreased prostate cancer cell growth and migration 33, 34 . Furthermore, increased PRKAA1 and decreased PRKAA2 expression independently predict poor prognosis in men with prostate cancer 33, 102 . Taken together, these results suggest that the two α catalytic subunits might have opposing actions in prostate cancer, with the α1 subunit acting oncogenically while the α2 subunit has tumour-suppressive properties.
Like AMPKα1, AMPKβ1 might also have oncogenic roles. The parts needed to generate certain effects (A, B,C) that are also known to be regulated by the described active complex are at location 1. Thus, when the active complex is at this site, the associated downstream processes are regulated to produce effects A, B and C. Processes regulated by the active complex that could produce effects C and Y but are located elsewhere, such as at location 2, will not be altered in this scenario. By contrast, when the complex is activated at location 2 and not location 1 such as in scenario 2, then only effects C and Y are produced and not effects A and B. In scenario 3, the complex is activated everywhere and all known processes controlled by the active complex will, therefore, be regulated, producing a broad range of effects (A, B, C, Y). b | Regarding AMPK-mediated cellular effects, different AMPK complexes are located throughout the cell (for example, cytoplasmic versus nuclear location). Depending on which of these complexes is activated (and it could be more than one), the net effect AMPK has on a cell will be the summation of the actions of all of the activated subcellular populations of AMPK and their associated downstream effector processes. AMPK, 5ʹ-AMP-activated protein kinase.
have an important role in prostate cancer. Thus, the cytoplasmic kinases that rapidly activate these AMPK complexes would be likely to also have important roles in prostate cancer. To that end, multiple groups have developed new molecular tools to assess AMPK activity at different subcellular locations 110, 111 . Here, the investigators created a series of genetically encoded Förster resonance energy transfer (FRET)-based reporters to visualize the phosphorylation of an AMPK target peptide. These key studies demonstrate that diverse upstream cues can activate unique subcellular AMPK populations. We hypothesize that each one of these unique subcellular AMPK complexes will be associated with -and can, therefore, regulate -a specific set of downstream signalling targets. As a result, depending on the duration and type of upstream signal, very different AMPK-mediated events would be elicited. Thus, the common oversimplification of general AMPK activity could lead to numerous misunderstandings and incorrect conclusions.
Regulation of AMPK AMPK can be activated by both allosteric modulation and post-translational modifications (FIG. 3) . Although this field is still hotly debated, AMPK's allosteric effects might prove minimal in comparison with the regulatory effects of post-translational modifications such as Thr172 phosphorylation [112] [113] [114] . Regardless, the most well-studied mechanism of AMPK activation is activation by AMP/ADP:ATP ratio. When the AMP/ADP:ATP ratio increases in the cell, AMP/ADP binds to the γ subunit of AMPK 3 . This binding causes a conformational change in the γ subunit that, in conjunction with a β-subunit myristoylation event 96 , exposes the Thr172 site located on AMPK's α-catalytic subunit. Phosphorylation of this site results in ~100-fold activation of AMPK 83, 115 . Thus, the phosphorylation of Thr172 is tightly regulated by upstream kinases and phosphatases.
The known Thr172-targeting kinases of AMPK are LKB1, TGFβ activated kinase-1 (TAK1) and calcium/calmodulin-dependent protein kinase kinase-2 (CaMKK2 or CaMKKβ). LKB1, which activates AMPK in response to energetic stress (such as high AMP/ADP levels), is a tumour suppressor that is thought to be the dominant AMPK kinase in the body. However, several lines of evidence indicate that LKB1 is not the predominant AMPK kinase in the prostate. First, although LKB1 is a known tumour suppressor for many types of cancer, prostate cancer is not one of them 116 . In support of this fact, Lkb1 deletion in Pten +/− mice was associated with an increase in tumour incidence for many cancer types but not prostate cancer 117 . Secondly, androgens were reported to decrease LKB1 expression and subsequent AMPK phosphorylation in mouse 3T3-L1 cells 118 . This effect is in direct contrast to the increase in AMPK phosphorylation observed following androgen treatment in prostate cancer cells 34, 35 . Thirdly, LKB1 is not highly expressed or regulated by the androgen receptor (AR) in prostate cancer cell models 119 . Fourthly, in a study that did suggest Lkb1 deficiency caused prostatic neoplasia in mice, the authors deleted Lkb1 using a mainly gastrointestinaltract-specific driven Cre rather than a prostate-specific driven Cre and, more importantly, observed continued high levels of Thr172-phosphorylated AMPK in Lkb1-deficient prostates 120 . These latter data led the authors to conclude that LKB1 was not an AMPK kinase in the prostate. To that end, LKB1 phosphorylates a number of other proteins and, therefore, if LKB1 were to have antiproliferative effects, these could be AMPKindependent 121 . For example, LKB1 is known to phosphorylate and stabilize the tumour suppressor PTEN, one of the most commonly mutated or deleted tumour suppressors in prostate cancer 122 . TAK1 is thought to be another activator of AMPK; however, more in-depth studies are needed to understand whether TAK1-mediated AMPK activation occurs in vivo and requires LKB1 (REFS 123,124) . MAP3K7, the The net phenotypic effect of each type of AMPK activation will be the summation of all the regulated downstream pathways, shifting the balance between oncogenic and tumour-suppressive AMPK signalling. In scenario 1, all downstream AMPK targets (both oncogenic and tumour-suppressive) are activated. Here, the tumour-suppressive functions could dominate. In scenario 2, activation of AMPK complexes is more selective, favouring the induction of oncogenic downstream processes. b | The type of upstream stimuli and, therefore, the manner in which cellular AMPK complexes are activated is likely to be influenced by both the location of upstream cues and AMPK complexes, which can be influenced by, among other aspects, the subunit composition, as well as the duration of signal. In this regard, in scenario 1, a persistent energetic stress such as high AMP or ADP levels would be able to activate the majority of AMPK complexes. By contrast, an upstream kinase with a more restricted location such as CaMKK2 (scenario 2) could only phosphorylate and activate local AMPK complexes, perhaps for a limited duration. This activation would lead to a restricted set of downstream processes that could be regulated by AMPK. ADP, adenosine diphosphate; AMP, adenosine monophosphate; AMPK, 5ʹ-AMP-activated protein kinase; CaMKK2, calcium/calmodulin-dependent protein kinase kinase-2. Nature Reviews | Urology gene encoding TAK1, is often deleted during development of prostate cancer [125] [126] [127] . However, these findings seem at odds with the increased Thr172-phosphorylated AMPK levels observed during the development of prostate cancer 7, 33, [125] [126] [127] . Alternatively, functional data indicate that TAK1's tumour suppressive effects are mediated through other stress kinases, namely p38 and c-Jun N-terminal kinase 128 . Taken together, these data suggest that TAK1 is not a major AMPK kinase in the prostate.
In 2005, CaMKK2 was identified by three separate groups to be a Thr172-targeting AMPK kinase [129] [130] [131] . In 2011, our group demonstrated that androgens, via AR, directly increase the expression of CAMKK2 (REF. 34 ). CaMKK2 phosphorylated and activated AMPK, leading to increased prostate cancer cell migration and invasion. The androgen response element, which we identified as being responsible for AR-mediated expression of CAMKK2 (REF. 34 ), is one of the most robust AR-binding sites in castration-resistant prostate cancer (CRPC) tissue 132 . Interestingly, CaMKK2 can augment AMPK activity under starvation or nutrient-rich conditions, suggesting that AR-CaMKK2 might potentiate AMPK activity independently of the environmental state. Two independent groups subsequently confirmed our findings and also demonstrated that CaMKK2 levels were elevated in clinical samples and correlate with disease progression 35, 36 . These findings correspond with the clinical data demonstrating that levels of the Thr172-phosphorylated form of AMPK are increased in prostate cancer and further increased in the advanced stages of the disease 7, 33, [125] [126] [127] . In 2015, Fu et al. 133 demonstrated that the tumour-suppressive microRNA miR-224 suppressed prostate cancer cell proliferation by decreasing CAMKK2 expression. In men with prostate cancer, combined low miR-224 and high CAMKK2 expression correlated with advanced disease and shortened survival. Remarkably, in this study the authors showed a proliferative role for CaMKK2 even in AR-negative DU145 cells, indicating that CAMKK2 might be expressed and driving oncogenic processes independent of AR in some of the most aggressive subtypes of prostate cancer. Collectively, these studies suggest that CaMKK2 is the dominant AMPK kinase in prostate cancer. In addition, new oncogenic roles for CaMKK2 in other cancer types such as stomach, liver, and brain have been observed [134] [135] [136] . However, although CaMKK2 seems to represent a promising target, additional work is needed to assess CaMKK2's functional role at different disease stages, regulation, and complete mechanisms of action, in order to understand if targeting it would have adverse effects.
AMPK can also be allosterically activated by two different pathways. The first requires binding of AMP, but not ADP, to the γ subunit. This direct allosteric activation by AMP does not require the β subunit myristoylation 96 . Secondly, AMPK can be pharmacologically activated by the binding of drugs such as A-769662 to the β subunit 137 . Although A-769662 and similar drugs function, in part, by inhibiting the dephosphorylation of Thr172, they also allosterically activate AMPK. As such, this type of activation does not necessarily require Thr172 phosphorylation of the α subunit, but does typically involve the autophosphorylation of Ser108 in the β subunit, which is often required for full AMPK activity 94 . Whether AMPK can be activated in the absence of Thr172 phosphorylation in response to endogenous signalling is not known.
Other mechanisms of AMPK regulation in prostate cancer also exist. For example, DNA-damaging agents, such as ionizing radiation and some chemotherapies, activate AMPK via ataxia telangiectasia mutated (ATM), an initiator of the DNA damage response [138] [139] [140] [141] [142] [143] . Whether LKB1 is required for this genotoxic response is still debated. Regardless, the outcomes of such studies are likely to have consequences for our understanding of therapeutic resistance 139, 140, [142] [143] [144] . Additionally, reactive oxygen species (ROS) can increase AMPK activity 38, 145, 146 , which is an important consideration, as oxidative stress is one of the hallmarks of aggressive prostate cancers 147 . Although the exact mechanisms by which ROS action on AMPK occurs are still being elucidated (for example, ROS might activate AMPK by altering ATM activity 144, 148 ), the process might function as a survival signal for cancer cells coping with the harsh tumour microenvironment 38 . Conversely, protein kinase B (AKT) has been reported to phosphorylate AMPK and reduce AMPK's activation by LKB1 (REF. 149 ). This mechanism would seemingly be an important feedback mechanism in prostate cancer, in which the most advanced stages exhibit elevated phosphoinositide 3-kinase (PI3K)-AKT signalling 102 . However, whether this type of regulation occurs in prostate cancer, in which levels of activated AMPK remain high even in the presence of increased AKT 7, 33, 37 and LKB1 does not seem to be the major AMPK kinase, remains unclear. Nature Reviews | Urology (TABLES 1,2), but whether many of these are regulated in prostate cancer or if they have a pathogenic role in the disease is not yet known and more work is needed to elucidate their regulation and role. An important point to remember is that the regulation of signalling pathways, such as those modulated by AMPK, rarely occurs in isolation. Most cancer signalling networks are influenced by additional oncogenic cascades such as PI3K-AKT or, as is typically the case in prostate cancer, AR.
Known AMPK targets AMPK has been classically defined as a master regulator of cellular metabolism in which the activation of AMPK by energetic stress leads to an overall increase in catabolic processes, which serve to breakdown nutrients for the generation of ATP. Simultaneously, AMPK shuts down a diverse range of anabolic processes to conserve ATP levels. Hence, many of AMPK's direct actions lead to an inhibition of proliferation as a mechanism to cope with the energetic stress -consistent with a role for AMPK as an initial tumour suppressor. For example, AMPK can phosphorylate wild-type p53 on serine-15 to potentiate its activity as a tumour suppressor, increasing p21 levels and causing a G1/S cell cycle arrest 195, 196 . However, whereas sustained AMPK activity causes wildtype p53-mediated cellular senescence, transient AMPK activation promotes cell survival following glucose starvation, consistent with a context-dependent, oncogenic role for AMPK 196 . Likewise, AMPK has been shown to phosphorylate and potentiate the transcriptional activity of Forkhead box protein O3 (FOXO3) 181, 182 . FOXO3 is a transcription factor that often functions as a tumour suppressor, but can also help manage metabolic stress [216] [217] [218] . Furthermore, increased AMPK activity has been shown to lead to the phosphorylation of threonine-198 of the cell cycle inhibitor p27 (REF. 26 ). Although phosphorylation causes a stabilization of p27, it also enables survival during starvation and/or metabolic stress through the induction of autophagy. However, whether this signalling cascade would be present in prostate cancer is not clear, as it requires LKB1 and LKB1 does not seem to be the dominant AMPK kinase in the prostate. In addition, the existence of mutations and/or deletions in several of these tumour suppressors, such as p53, suggest that many of these tumour-suppressive signals might not even exist in advanced prostate cancer, as any AMPK-mediated effects on p53 are no longer relevant when p53 is not present.
Metabolic actions
One of the first described activities of AMPK was its ability to regulate lipid metabolism 166, 219, 220 via the phosphorylation and inhibition of several proteins such as ACC1, ACC2, 3-hydroxy-3-methyl-glutaryl-CoA (HMGCR), and the lipogenic transcription factors sterol regulatory element binding proteins-1 and 2 (SREBP-1 and SREBP-2) and hepatocyte nuclear factor 4A (HNF4A) 166, [219] [220] [221] [222] . The exact biological effect of AMPK in this scenario is determined by which specific proteins are targeted. For example, phosphorylation and inhibition of ACC1 blocks de novo fatty acid synthesis, whereas inhibition of its related isoform ACC2 increases fatty acid oxidation. AMPK has been shown to promote cancer under conditions of matrix detachment or glucose deprivation by inhibiting ACC1 and ACC2, respectively, resulting in the maintenance and production of protumorigenic NADPH levels 32 . Regardless, how AMPK signalling will affect prostate cancer development through any of these downstream targets such as ACC1 is unclear, as many of the inhibitory effects of AMPK, such as AMPK-mediated phosphorylation and inhibition of ACC1, are overridden by AR signalling. For example: increased lipogenesis is one of the hallmarks of prostate cancer 223 ; AR increases the expression of several enzymes involved in de novo lipogenesis -including fatty acid synthase, ATP-citrate lyase, HMGCR, ACC, and farnesyl diphosphate synthase -through the increased expression of the SREBF1 (which encodes SREBP-1), SREBF2 (which encodes SREBP-2) and SCAP, which further activates the SREBPs 223, 224 . Thus, when AR signalling is present -as is the case in most prostate cancers -cells can simultaneously maintain AMPK signalling and protumorigenic lipogenesis.
Prostate cancer is metabolically unusual compared with many other cancer types. In contrast to benign prostate tissue, prostate cancer exhibits increased fatty acid and glucose oxidation [225] [226] [227] . This enhanced tri carboxy lic acid (TCA) cycle flux paradoxically occurs despite the accumulation of intracellular lipid levels. Increased TCA cycle flux is now known to be partially caused by decreased levels of Zn 2+ in transformed prostate cells 225, [228] [229] [230] . The decreased Zn 2+ level leads to a derepression of the enzyme aconitase, facilitating the forward metabolism of substrates through the cycle. In prostate cancer, this process can also be augmented by the AMPK-mediated induction of peroxisome-proliferator-activated receptor γ co-activator 1α (PGC-1α), a master regulator of mitochondrial bio genesis 33, 174 . Importantly, this entire cascade can be activated by AR
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. The precise mechanism of AMPK's induction of PGC-1α is not known and could involve both direct and indirect effects 33, 174, 206 . Furthermore, other mechanisms by which AR-mediated AMPK signalling increases fatty acid oxidation in prostate cancer might also exist 28, 32, 180, 194 . Curiously, some additional AMPK targets are known to regulate mitophagy and fragmentation, suggesting that AMPK signalling could simultaneously promote the breakdown of old mitochondria and the synthesis of new mitochondria, perhaps improving cellular function 191, 203, 215 . To what degree this process occurs in prostate cancer is currently not known. In addition to alterations in mitochondrial metabo lism, AMPK can modulate other aspects of sugar metabolism. For example, AMPK can directly phos phory late two of the four isoenzymes of 6-phosphofructo 2-kinase/fructose-2,6-bisphosphate 2-phosphatase (PFKFB), an enzyme that represents the rate-limiting step of glycolysis 40, 175, 176, 231, 232 . These phosphorylation events on PFKFB2 and PFKFB3 increase their kinase activity and, therefore, promote forward flux through glycolysis. An additional level of regulation is likely to exist in prostate cancer, because AR signalling increases the expression of PFKFB2 (REF. 233 ). PFKFB2 has also been demonstrated to be phosphorylated and activated at the same AMPK-target site in response to oncogenic PI3K-AKT signalling 102, 234 . Although AR-AMPK-PFKFB signalling is thought to occur in prostate cancer 35 , the extent to which each isoform is stimulated by AR and/or AMPK, how the isoforms are regulated, and their functional roles are incompletely defined.
Beyond its role in glycolysis, AMPK might also have a more general function in glucose uptake. Although no data are currently available to illustrate this hypothesis, AMPK-mediated processes identified in other tissues might be relevant in prostate cancer. For example, AMPK is known to induce the translocation of glucose transporter type 4 (GLUT4) in muscle and fat via the direct phosphorylation and regulation of TBC1D1 and TBC1D4 (also known as AS160), molecules that control vesicle trafficking 155, 158, 235, 236 . Additionally, AMPK has been reported to increase GLUT1 levels through a variety of mechanisms [211] [212] [213] . However, similar to the regulation of PFKFB2, other oncogenic cues can influence glucose uptake and, therefore, need to be considered. To that end, PI3K-AKT signalling can increase glucose transporter translocation and function in other cancers 237 . Similarly, GLUT1 levels can be stimulated by MYC, another commonly amplified oncogene in prostate cancer 102, 237 . In addition, both PI3K-AKT and MYC can increase the expression of HK2, the first step of glycolysis, and might, therefore, further augment glucose uptake and metabolism 238, 239 .
AMPK and autophagy.
The cellular recycling process of autophagy is increased following AMPK activation 215, 240, 241 . Similar to AMPK, initial research first defined autophagy as a tumour-suppressive process 242, 243 , but other studies have since identified an oncogenic role for autophagy, particularly in the late stages of the disease 244, 245 . These findings extend to prostate cancer, in which autophagy has been implicated in disease progression 30, [246] [247] [248] . Despite initial indications of a functional role for autophagy in prostate cancer, how this process operates during the different stages of the disease and how it is regulated are still not clear. For example, how AR regulates autophagy is debated 30, 246, 247, 249 , which is somewhat surprising given AR's robust induction of AMPK in prostate cancer [33] [34] [35] [36] 132 . The discrepancies in the data might be due to variations in the stimuli duration (sustained versus transient), use of indirect or nonselective modulators of AMPK and autophagy -such as 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), metformin, or chloroquineand treatment conditions. Regarding the last point, most experiments that are performed to examine the effects of hormones are performed using media that contains charcoal-stripped serum, a condition commonly referred to as 'androgen-starved' . However, as well as removal of most androgens, charcoal-stripping of serum also removes many other steroid hormones and peptide growth factors that could affect AMPK and autophagy. To that end, it is worth noting that switching AR-negative PC3 prostate cancer cells from regular serum-containing media to the androgen-starved, charcoal-stripped-serum-containing media activates AMPK and autophagy in an AR-independent manner (D. Frigo, unpublished work). Clearly, additional studies using more sophisticated molecular and genetic approaches are needed to help resolve these discrepancies. AMPK can directly increase autophagy through the phosphorylation of serine/threonine protein kinase ULK1 (ULK1) and possibly ULK2 (REFS 190, 191, 240) . In 2013, AMPK was also shown to increase autophagy via the direct phosphorylation of phosphatidylinositol 3-kinase VPS34 and Beclin-1 (REF. 171 ). Moreover, AMPK can indirectly increase autophagy by decreasing mTOR signalling, an inhibitor of autophagy. This inhibition of mTOR -and thus derepression of autophagy -is thought to occur predominantly through two mechanisms. First, AMPK can directly phosphorylate the mTOR adaptor protein regulatory-associated protein of mTOR (raptor), inducing the binding of 14-3-3 protein isoforms to raptor and inhibiting the mTORC1 complex 173 . Second, AMPK can directly phosphorylate tuberin (also known as TSC2) to potentiate its repressive effects on mTORC1 (REF. 172 ). AMPK might also regulate mTOR signalling through the phosphorylation and inhibition of upstream components of the PI3K-AKTmTOR pathway such as insulin receptor substrate-1 (REF. 179 ). However, this regulatory mechanism might not be prevalent in the disease, given the propensity of high levels of PI3K-AKT signalling in advanced prostate cancers. In addition, AMPK's effects on mTOR signalling in prostate cancer are difficult to predict, owing to the unusual crosstalk between the two pathways.
In contrast to the dogma described in conventional physiology, AMPK and mTOR signalling can simultaneously occur in prostate cancer 33, 34, 250, 251 . Thus, caution should be used when extrapolating results from basic biology, or even other cancer types, regarding AMPK and mTOR in prostate cancer. Why some crosstalk that occurs in other tissues does not occur in prostate cancer is not entirely clear, but some evidence is now beginning to address how this divergence could mechanistically occur. In prostate cancer, AR signalling increases the expression of a splice variant of TSC2, termed TSC2A, that cannot block mTOR signalling 252 . The existence of TSC2A results in a unique situation in which the cancer cell can concurrently activate two signalling pathways that are normally opposing. Hence, prostate cells can benefit from the procancer effects of both pathways.
Nonmetabolic roles
Although AMPK is defined as a master regulator of cellular metabolism, new findings indicate AMPK might have several nonmetabolic roles that could affect processes of pathological importance in cancer. For example, AMPK seems to have an important role in mitosis, through several mechanisms including targeting components of the mitotic spindle assembly, regulating the breakdown and assembly of the Golgi apparatus, and modulating the cytoskeleton 161, 200, 209, [253] [254] [255] . These effects might at first appear contrary to the induction of tumour-suppressive factors such as p53, but could function collectively as a protective checkpoint, assuring that cell cycle progression does not occur prematurely. This type of 'cautious' signalling would be in contrast to other reports of more direct oncogenic roles for AMPK, such as acting as an essential downstream effector of oncogenic HRasV12 or Pten deletion that functions to directly phosphorylate and inhibit the tumour suppressor retinoblastoma-associated protein (Rb) 24 . To what extent this signalling occurs in advanced prostate cancer -in which Rb is often mutated or deleted -is currently unknown 256 .
Actions in the nucleus
Finally, one of the emerging areas of interest is AMPK's actions in the nucleus. Early reports of AMPK functions largely pertained to cytoplasmic AMPK activity, but evidence suggests that this kinase has additional roles in transcription and epigenetic mechanisms. To that end, AMPK can regulate the activity of several transcription factors and transcriptional co-regulators such as HNF-4α, cAMP-response element binding protein (CREB), FOXO3, PGC-1α, CRTC2 and class IIa histone deacetylases 33, 164, 174, 180, 181, 201, 202, 205, 221, [257] [258] [259] [260] [261] . In addition, AMPK was reported to interrupt the association of nuclear receptors with the co-activator p300 (REFS 95, 187) . This interruption could have important implications in prostate cancer, given the key role of AR in the disease. Correspondingly, AMPK was reported to inhibit AR activity 15 . However, this study seems to be in direct contrast to data from Karacosta et al. 36 indicating that CaMKK2 potentiates AR activity in prostate cancer. In our own studies, we have been unable to detect either agonistic or antagonistic effects of CaMKK2 and/or AMPK on AR activity, with the caveat that we have only explored a limited gene set (D. Frigo unpublished work). Hence, differences between groups might be attributable to variations in the subsets of AR-target genes being regulated. Certainly, this area of research needs further investigation.
Disease stage roles for AMPK
The predominant view of those supporting a contextdependent role for AMPK suggests that AMPK first acts as a tumour suppressor early in tumorigenesis and then later shifts towards a more oncogenic role in the advanced stages of the disease, contributing to therapy resistance and cancer reoccurrence 3, 100, 121, [262] [263] [264] [265] [266] [267] [268] [269] [270] [271] . Early on, AMPK would be activated in response to inhibitory mutations in tumour-suppressor genes or gain-offunction events in known oncogenic pathways. This activation would lead to the classic AMPK-mediated catabolic functions including inhibition of oncogenic mTOR signalling and/or lipogenesis as well as regulation of the cell cycle. As the tumour evolves, the cancer cells encounter various stresses such as hypoxia, matrix detachment, and starvation, in addition to exposure to chemotherapy, which also increases cellular stress. At this advanced stage, AMPK is hypothesized to drive cancer progression by promoting metabolic plasticity, resistance to cellular stress and, therefore, cell survival.
Although the early tumour-suppressive and late oncogenic paradigm could indeed be true for a number of cancers, prostate cancer might be different. Contrary to many other cancers, clinical data suggest that AMPK activity is increased in both early and late disease stages 7, 33, 37, 271 . In addition, many of the classic tumour-suppressive functions of AMPK are overridden in prostate cancer by other canonical signalling pathways. For example, AR's ability to increase mTOR signalling and lipogenesis in the presence of AMPK signalling might negate two of the major tumour-suppressive networks. However, prostate cancer is an extremely heterogeneous disease 272 and, as such, broad generalizations could lead to inaccuracies. Future studies are required to better characterize AMPK's disease stage-specific roles and whether these roles vary among prostate cancer subtypes.
Targeting AMPK Several strategies are currently being employed to modulate AMPK activity in cancer. However, whether agonists or antagonists should be used given AMPK's contextdependent role (oncogenic versus tumour suppressive) is unclear. Furthermore, the pivotal roles of AMPK in numerous physiological processes might ultimately preclude AMPK itself from ever being a viable therapeutic target, as alteration of this key signalling molecule is likely to have multiple side effects.
Interest in targeting AMPK started when retrospective studies of diabetic patients taking the biguanide drug metformin reported decreased risks of a variety of cancer types including prostate cancer [59] [60] [61] [62] . These reports were extremely exciting, as metformin is an ideal candidate drug for repurposing: it is inexpensive, widely available, easy to use, and safe at the concentrations used to treat diabetes. However, subsequent retrospective and prospective studies have called into question the anticancer effects of metformin in prostate cancer [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] . The debate regarding metformin as an anticancer drug continues, partly because its potential anticancer mechanism of action is still not clear.
Two potential mechanisms of action have been proposed to explain metformin's effect on cancer, categorized under indirect or direct effects. The most obvious indirect effect is via its ability to reduce circulating levels of insulin, a known mitogen and antiapoptotic signal for some cancers 273 . However, whether the metformininduced changes in insulin levels would be substantial enough, particularly in nondiabetics, to alter tumour biology, is not known 274 . By contrast, numerous preclinical studies have shown direct tumour-suppressive effects using in vitro and in vivo models 275, 276 . One of the major concerns in the ongoing clinical trials is whether a high enough concentration of metformin could reach the tumour cell to have direct antitumour effects; metformin concentration depends on both the bioavailability of the drug and its cellular uptake. Doses of metformin that are used to treat diabetic patients achieve plasma concentrations of 40-70 μM in the portal vein, in which the drug is first absorbed and shuttled 277 . After liver uptake (of note, metformin is not metabolized in animals or humans and is eliminated by the kidneys unchanged), systemic plasma concentrations drop to ~10-40 μM (REF. 278 ). The micromolar concentrations used to treat diabetics are clearly enough to decrease glucose production in the liver, most likely functioning -at least partly -via AMPK. However, even this point is debated 279, 280 . An initial concern with such studies surrounded the fact that the majority of in vitro studies required high (millimolar) concentrations of metformin to inhibit the respiratory chain complex 1 and have tumour-suppressive effects 281 , presenting an obstacle for the hypothesized model that metformin has direct tumour-suppressive effects. In this case, sufficiently high drug concentrations could not reach the tumour, indicating that any potential anticancer effects would have to be mediated through an indirect mechanism; in order to provoke a direct tumour-suppressive effect, new clinical trials using higher metformin doses would have to be considered. However, increasing the dose might defeat one of the major benefits of repurposing metformin -it is very safe at the doses used to treat diabetics, but higher doses might cause dangerous adverse effects such as lactic acidosis. However, two brief letters published back-to-back in Cell Metabolism in April 2016 suggest the doses being used in preclinical animal models might be sufficient to model effective clinical doses in humans 282, 283 . Using liquid chromatography-mass spectrometry, Dowling et al. 282 demonstrated that, in a xenograft model of colorectal cancer, mice given drinking water containing 5 mg/ml metformin (a comparable dose to that previously used in similar studies), achieved plasma and -surprisingly -tumour concentrations of ~30 μM, a concentration that was sufficient to increase AMPK activity (assessed by AMPK Thr172 phosphorylation). Whether metformin-treated mice also exhibited reduced numbers of tumours and tumour size in this experiment was not reported. To achieve similar phospho-AMPK Thr172 levels in cell culture, HCT116 colon cancer cells had to be treated with 10-20 mM metformin, a dose >300-fold greater, indicating that metformin is much more readily taken up in vivo than in vitro. Interestingly, samples taken from nondiabetic patients with breast cancer given metformin exhibited considerably lower plasma metformin levels (~2.8 μM) than diabetic patients (≤25 μM), suggesting that increased doses might be needed for anticancer efficacy, particularly in nondiabetic patients. These results once again call into question a direct antitumour effect of metformin, as reported in previous clinical studies -exactly how the reported beneficial effects of metformin could be due to direct actions on the tumour when the intratumoral metformin concentration was insufficiently high is not clear.
Chandel and colleagues 283 performed a similar study using the same HCT116 colon cancer xenograft model with a 1.25 mg/ml solution of metformin -a concentration the investigators had previously shown to inhibit tumour growth in this model (although a functional role for AMPK was never tested). In this study, they detected both plasma and tumour metformin concentrations in the range of 3.2-12.4 μM, levels, which can be achieved in routine diabetes treatment 284 . In addition, they noted that due to its cationic nature, metformin is predicted to accumulate 100-500-fold in the mitochondria because of the membrane potential. Collectively, these results indicate that the doses currently being used in ongoing clinical trials are reasonable. However, the question remains of whether doses currently given to diabetic patients are sufficient to block mitochondrial activity in patient tumours, and, if so, then why the previous epidemiological studies did not consistently demonstrate anticancer effects. More importantly, we must question why no survival benefit was observed following the first formal blinded clinical trial of metformin, even though plasma drug levels were in the micromolar range 285 . Further work is certainly needed in this area, and determining whether isolated mitochondria from treated patients contain significantly enriched metformin levels and whether additional biological factors like the expression of membrane transporters influence drug efficacy will be especially important.
The hydrophilic nature of metformin likely prevents it from passively diffusing through plasma membranes. Hence, cellular uptake is controlled by cationic transporters such as octamer-binding protein (OCT) 1, OCT2, and OCT3 (encoded by the genes SLC22A1, SLC22A2, and SLC22A3, respectively) 286 . OCT3 and SLC22A3 are highly expressed in the prostate, indicating that active metformin uptake should be possible in this tissue 287 . However, low SLC22A3 expression is a strong predictor of poor prognosis in prostate cancer patients [288] [289] [290] [291] . Whether changes in SLC22A3 expression could, in part, explain some of the differences between the contrasting retrospective analyses of metformin's effects on prostate cancer remains to be determined.
One would predict that tumours with low OCT3 levels would have decreased sensitivity to metformin so -as risk allele variants associated with SLC22A3 expression are known 288, 289, 291, 292 -these could be screened before selection of patients for future clinical trials in order to mitigate this obstacle.
Despite the controversies surrounding the clinical studies, enthusiasm for metformin is still high, owing to preclinical studies that demonstrated potent therapeutic effects across a broad range of cancers 293 . Researchers have hypothesized that the drug's anticancer effects could be mediated through AMPK, as metformin has been shown to increase cellular AMPK activity 20, 222, [294] [295] [296] . Metformin, like other biguanides such as phenformin, can indirectly activate AMPK by inhibiting complex I of the electron transport chain 51, 63, 279, 281, 297, 298 . This binding causes cellular energy stress, increasing the AMP:ATP ratio, which could lead to activation of AMPK complexes throughout the cell. Further studies suggested an additional metformin-initiated, genotoxic activation of AMPK 299 ; however, the exact mechanism of this effect has been called into question 300, 301 . Like metformin, a number of other activators of AMPK, both synthetic (for example phenformin, AICAR, rosiglitazone, and 2-deoxyglucose) and natural (such as salicy late, resveratrol, and berberine), can inhibit cancer cell growth, migration and/or invasion 1, 7, 20, 296, 302, 303 . By contrast, AICAR was able to rescue the inhibition of prostate cancer cell proliferation caused by molecular or pharmacological inhibition of CaMKK2 (REF. 35 ). Many of these compounds have been demonstrated to be highly nonspecific and clearly have tumour-suppressive (and possibly oncogenic) properties independent of the AMPK pathway 45, 47, 49, 50, 53, 54, 279 , so additional stress signalling pathways might instead be responsible for the decreased cellular growth following the onset of stress. In fact, induction of cell death by several AMPK 'activators' can be exacerbated by knocking out AMPK, indicating that AMPK is often activated in response to these drugs as a final survival effort [21] [22] [23] 26, [28] [29] [30] [31] 53, 172, 180 . In this regard, use of these compounds in combination with inhibitors of AMPK could be warranted. Although drugs like metformin might, indeed, have tumour-suppressive effects in some contexts, this effect might be attributable to systemic effects rather that direct targeting of the cancer cell itself. Genetic studies using conditional knockout and transgenic animals will be essential to elucidate these mechanisms of action.
Agonists or antagonists?
To avoid some of the uncertainties inherent in using indirect activators of AMPK, direct activators of AMPK, such as OSU-53 and PT1, have been identified and shown to have tumour-suppressive properties in several breast and prostate cancer cell lines 11, 12, 17 . However, the exact AMPK binding sites for some of these compounds are incompletely defined 11, 13, 14, 304 and the off-target effects of these drugs are unclear 55 . One of the novel direct activators, MT 63-78, was able to decrease the proliferation of prostate cancer cells in vitro as well as suppress tumour growth in vivo 17 . MT 63-78, in a similar manner to A-769662 and salicylates, allosterically activates AMPK by directly binding to the β1 regulatory subunit 17, 303, 305 . This mechanism seems at odds with the clinical data and functional studies, which suggest that the β1 subunit is oncogenic 103, 106 . This apparent conundrum might be due to differences in the duration of stimuli. For example, transient pulses of AMPK activity might only lead to the phosphorylation and modu lation of the most sensitive downstream AMPK targets; however, a sustained robust activation of AMPKsuch as in the presence of pharmacological activation by MT 63-78 -might hyperactivate an increased number of AMPK complexes, modulating a larger set of downstream targets. In this latter case, the broad activation of downstream targets would have tumour-suppressive effects, such as increased cellular stress.
Although many studies demonstrate that AMPK activity blocks prostate cancer cell growth, antagonists of AMPK, such as compound C, have also been shown to inhibit prostate cancer cell proliferation and migration [29] [30] [31] 34, 37 . In addition to compound C, other inhibitors of AMPK have been identified, including the tyrosine kinase inhibitors sunitinib and midostaurin, which have potent anticancer effects in vitro and in vivo in a variety of cancers 306, 307 . However, like most AMPK agonists, these drugs have well known pleiotropic effects and are, therefore, likely to also possess AMPK-independent tumour-suppressive properties 48, 50, 308, 309 . Part of the rationale for the use of AMPK activators in cancer is AMPK's known ability to inhibit oncogenic cellular processes such as de novo lipogenesis and mTOR signalling. However, inhibitors of lipo genesis and mTOR already exist, which raises the question of whether we could instead target the specific oncogenic, downstream processes of AMPK signalling. Furthermore, AMPK agonists might not have a strong effect in prostate cancer, in which AR and PI3K-AKT are commonly hyper activated and increase lipogenesis and mTOR signalling, thus overriding the inhibitory effects of AMPK on these processes. Conversely, inhibition of AMPK might augment lipogenesis and/or mTOR signalling. In this regard, combined treatment with inhibitors of AMPK and lipogenesis and/or mTOR might be useful. However, whether such an approach would have severe side effects, given the important roles of these processes throughout the body, remains to be determined.
The need to identify upstream and downstream targets. A key step that needs to occur in our understanding of AMPK's actions in prostate cancer is the identification of the downstream targets of AMPK that are the drivers of the disease. Elucidation of these pathways might reveal more selective therapeutic targets. Alternatively, identification of tissue-specific or disease-specific regu lators of AMPK might also reveal viable new targets. CaMKK2, as an upstream kinase of AMPK, could represent one such target. CaMKK2 is increased in prostate cancer, has a restricted expression profile, and mediates several oncogenic processes. A cell-permeable inhibitor of CaMKK2, STO-609, has been available since 2002 (REF. 310 ) and has been shown to reduce androgen-sensitive prostate cancer proliferation, migration, and invasion, as well as restrict the growth of castration-resistant tumours 34, 35 . However, STO-609 might not be an ideal lead compound due to its high lipophilicity and relatively flat and rigid structure. Thus, STO-609, or a similar compound with improved pharmacokinetic and pharmacodynamic properties, could have therapeutic value in prostate cancer.
Conclusions
To understand AMPK's role in prostate cancer, one must first identify the type of stimulus (that is, how AMPK is activated), the composition of the hetero trimers, and the downstream driver pathways that are being modulated; all three are interconnected. The type and duration of the stimulus will dictate which sub cellular AMPK complexes are activated and for how long. The amount of AMPK complexes at each subcellular site will be influenced by the subunit composition. The location of the complexes might also be regulated by posttranslational modifications and/or additional anchoring mechanisms. At this time, what factors determine the distribution of the complexes is poorly understood. Each distinct AMPK complex is associated with a set of targets that can be phosphorylated when that particular complex is activated, but many of these downstream processes are influenced by other oncogenic signals, such as AR and/or MYC. For instance, even though increased AMPK can lead to the phosphorylation of ACC1, an event known to block de novo lipogenesis, in most prostate cancers AR signalling probably overrides this blockade by increasing the expression of an entire network of enzymes involved in lipogenesis. Taken together, the upstream cues determine which specific AMPK complexes are activated and, therefore, which downstream biological processes will be modulated. An example of these divergent outcomes could be the activation of AMPK by prolonged energetic stress (for example, during metformin treatment) versus the controlled activation of a subpopulation of AMPK by an upstream kinase such as CaMKK2. High levels of AMP caused by prolonged energetic stress would lead to the robust activation of a large number of AMPK complexes throughout the cell, modulating most of the known AMPK targets and processes. Compare this effect to the activation by CaMKK2, a major upstream kinase of AMPK in prostate cancer: CaMKK2's predominant cytoplasmic localization and requirement for a direct association with AMPK to phosphorylate and activate the protein indicates that CaMKK2 will only regulate the activity of a small restricted set of AMPK complexes, which are located primarily in the cytoplasm. This effect is exacerbated in prostate cancer, in which the α1 isoform of the catalytic subunit, which tends to be located in the cytoplasm 90, 91 , is the predominant form 33, 34, 101 . Interestingly, the majority of AMPK's tumour-suppressive effects have, thus far, been associated with its nuclear functions (for example p53, p21, and p27 induction, p300 inhibition). Hence, stimuli that favour the activation of non-nuclear AMPK complexes might, therefore, favour the induction of more oncogenic processes. Given AMPK's ubiquitous and diverse roles throughout the body, the broad targeting of AMPK might not be a viable option in cancer. Furthermore, the use of direct AMPK activators or inhibitors is likely to be affected by the counterproductive activation of some AMPKmediated oncogenic pathways and impairment of other AMPK-mediated tumour-suppressive signals. The elucidation of downstream AMPK-mediated processes will, hopefully, uncover the driver signalling events and highlight new therapeutic targets in the AMPK pathway. Alternatively, identification and targeting of the prostate-cancer-specific upstream cascades that favour the activation of these downstream oncogenic events could have greater overall efficacy, as it would affect multiple AMPK-mediated procancer processes. In addition, the tissue-specific and disease-specific nature of the upstream signal could offer a unique therapeutic target in prostate cancer, potentially mitigating side effects. Finally, although the model of AMPK signalling outlined here is specific to prostate cancer, the molecular concepts described could be extended to explain AMPK actions in other cancers, diseases, and even nondisease states.
